Stockscreener 앱 받기
148.74
0.69%
-1.04
시간 외 거래:
148.74
전일 마감가:
$149.78
열려 있는:
$150.49
하루 거래량:
656.67K
Relative Volume:
0.66
시가총액:
$7.31B
수익:
$4.06B
순이익/손실:
$413.08M
주가수익비율:
18.57
EPS:
8.01
순현금흐름:
$560.48M
1주 성능:
-10.89%
1개월 성능:
-6.09%
6개월 성능:
-9.19%
1년 성능:
-26.34%
1일 변동 폭
$148.13
$152.12
1주일 범위
$148.13
$168.61
52주 변동 폭
$91.86
$230.02
Charles River Laboratories International Inc Stock (CRL) Company Profile
명칭
Charles River Laboratories International Inc
전화
781-222-6000
주소
251 BALLARDVALE ST, WILMINGTON, MA
CRL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
148.74 | 7.38B | 4.06B | 413.08M | 560.48M | 8.01 |
|
TMO
Thermo Fisher Scientific Inc
|
460.72 | 169.53B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
200.56 | 139.75B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
658.06 | 49.94B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
114.62 | 32.16B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
179.86 | 30.17B | 15.50B | 1.33B | 2.16B | 7.34 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-05-14 | 업그레이드 | TD Cowen | Hold → Buy |
| 2025-05-08 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2025-03-21 | 다운그레이드 | Goldman | Buy → Neutral |
| 2025-03-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2025-03-03 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2025-01-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-01-17 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-11-18 | 다운그레이드 | CLSA | Hold → Underperform |
| 2024-11-07 | 업그레이드 | CLSA | Underperform → Hold |
| 2024-10-23 | 개시 | CLSA | Underperform |
| 2024-10-14 | 개시 | Redburn Atlantic | Sell |
| 2024-10-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-01 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2024-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-08-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | 다운그레이드 | Argus | Buy → Hold |
| 2024-06-07 | 개시 | Mizuho | Neutral |
| 2024-06-06 | 개시 | Goldman | Buy |
| 2024-02-15 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2023-09-13 | 개시 | TD Cowen | Market Perform |
| 2023-07-10 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-02-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-01-12 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-09-30 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-08-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-05-24 | 개시 | Guggenheim | Neutral |
| 2022-04-25 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-07 | 개시 | Stephens | Overweight |
| 2022-02-17 | 재확인 | BofA Securities | Buy |
| 2022-02-17 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-02-17 | 재확인 | Deutsche Bank | Buy |
| 2022-02-17 | 재확인 | Morgan Stanley | Overweight |
| 2022-02-17 | 재확인 | UBS | Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2020-12-16 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-07-01 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2020-05-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-04-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-03-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-02 | 개시 | Deutsche Bank | Buy |
| 2020-02-18 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2020-01-10 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-01-08 | 개시 | Wells Fargo | Overweight |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-18 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-06-10 | 개시 | SVB Leerink | Outperform |
| 2019-04-30 | 재개 | Evercore ISI | Outperform |
| 2018-12-14 | 개시 | Deutsche Bank | Buy |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-08-23 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-07-17 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-06-15 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-02-14 | 업그레이드 | SunTrust | Hold → Buy |
모두보기
Charles River Laboratories International Inc 주식(CRL)의 최신 뉴스
Stock Analysis | Charles River Laboratories International OutlookMixed Signals Amid Earnings Watch - AInvest
Charles River Laboratories International 2025 Q2 Earnings Misses Targets as Net Income Drops 44% - AInvest
Charles River Laboratories International, Inc. (NYSE:CRL) Q2 2025 Earnings Call Transcript - Insider Monkey
Charles River Laboratories International Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Charles River Laboratories Q2 2025 Earnings Preview - MSN
Charles River Laboratories Reports Q2 2025 Earnings - TipRanks
Charles River Laboratories International Q2 2025 Earnings Call Transcript - MarketBeat
Charles River Laboratories International 2025 Q2 Earnings Beats Expectations as Net Income Drops 44.1% - AInvest
Charles River: Q2 Earnings Snapshot - Milford Mirror
Charles River Labs Reports Mixed Q2 Earnings Call - TipRanks
Charles River Laboratories Shares Drop 10.25% Despite 49.73% Volume Surge Ranking 339th in Market Activity as Order Cancellations Weigh on Investor Sentiment - AInvest
Charles River Laboratories International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Charles River (CRL) Q2 EPS Jumps 11% - The Globe and Mail
Charles River (CRL) Q2 EPS Jumps 11% - The Motley Fool
Charles River Labs stock price target raised to $175 by BofA Securities - Investing.com India
Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing - Benzinga
Charles River: Margin Fears Outweigh Solid Q2 (NYSE:CRL) - Seeking Alpha
Charles River Labs cleared in DOJ monkey investigation, provides strategic review update - The Business Journals
Deutsche Bank Adjusts Price Target on Charles River Laboratories International to $185 From $180 - MarketScreener
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates - sharewise.com
Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View - Yahoo Finance
Charles River Laboratories (NYSE:CRL) Delivers Impressive Q2 - Yahoo Finance
Charles River Labs Q2 2025 slides: Beats expectations, raises guidance amid stabilizing demand - Investing.com Canada
Charles River Laboratories Announces Second-Quarter 2025 Results - BioSpace
Charles River Laboratories Fiscal Q2 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Updated - MarketScreener
Charles River Laboratories Reports Q2 2025 Revenue of $1.03 Bill - GuruFocus
Charles River Labs soars 6.9% after crushing Q2 earnings expectations By Investing.com - Investing.com South Africa
Charles River Labs soars 6.9% after crushing Q2 earnings expectations - Investing.com
Charles River Laboratories earnings beat by $0.62, revenue topped estimates - Investing.com Canada
Charles River Laboratories (CRL) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
How volatile is Charles River Laboratories International Inc. stock compared to the marketBuild wealth steadily with proven strategies - Jammu Links News
Charles River Laboratories International Inc. Stock Analysis and ForecastFree Stock Market Knowledge Sharing - Jammu Links News
What is Charles River Laboratories International Inc. company’s growth strategyBuild a winning investment portfolio - Jammu Links News
Is it the right time to buy Charles River Laboratories International Inc. stockIdentify winners with top-tier analysis - Jammu Links News
What is the dividend policy of Charles River Laboratories International Inc. stockRobust investment performance - Jammu Links News
How strong is Charles River Laboratories International Inc. company’s balance sheetMarket-leading profit generation - Jammu Links News
What are Charles River Laboratories International Inc. company’s key revenue driversAchieve breakthrough gains with expert advice - Jammu Links News
What makes Charles River Laboratories International Inc. stock price move sharplyMaximize returns with strategic trading plans - Jammu Links News
What institutional investors are buying Charles River Laboratories International Inc. stockFree Smart Trading Workshop - jammulinksnews.com
Charles River Laboratories International, Inc. (NYSE:CRL) Looks Inexpensive But Perhaps Not Attractive Enough - 富途牛牛
Should I hold or sell Charles River Laboratories International Inc. stock in 2025Post Market Planner For Smart Trading - Jammu Links News
What are the latest earnings results for Charles River Laboratories International Inc.Pre Market Target Finder For 2025 - Jammu Links News
How does Charles River Laboratories International Inc. generate profit in a changing economyEntry Signal Data Feed With Low Risk - Jammu Links News
Charles River and BioTech Social Inc. Join Forces to Enhance Crowdfunding for Cell and Gene Therapy Developers - AInvest
Charles River explores crowdfunding partnership with BioTech Social - StreetInsider
Charles River Laboratories International Inc (CRL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.15%
자본화:
|
볼륨(24시간):